Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 5,657 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Renal Disorder Clear all
Completed Phase 2 Interventional Results available

Pazopanib in Treating Patients With Metastatic Urothelial Cancer

NCT00471536
View directory record Official record
Conditions
Distal Urethral Cancer, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder, Urethral Cancer Associated With Invasive Bladder Cancer
Interventions
pazopanib hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
7
States / cities
Jacksonville, Florida • Baltimore, Maryland • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Jul 23, 2026, 10:45 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function

NCT07342881
View directory record Official record
Conditions
Chronic Hepatitis B Infection
Interventions
Pevifoscorvir Sodium (ALG-000184)
Drug
Lead sponsor
Aligos Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Orlando, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jul 23, 2026, 10:45 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Preoperative Use of Darifenacin (Enablex) to Alleviate Postoperative Ureteral Stent Pain

NCT01189071
View directory record Official record
Conditions
Overactive Bladder, Renal Colic, Pain, Postoperative
Interventions
Darifenacin
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 20, 2016 · Synced Jul 23, 2026, 10:45 PM EDT
Terminated Phase 4 Interventional Results available

Nesiritide and Renal Function After the Total Artificial Heart

NCT01836809
View directory record Official record
Conditions
Congestive Heart Failure, Cardiorenal Syndrome
Interventions
nesiritide, placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Jul 23, 2026, 10:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet

NCT02108639
View directory record Official record
Conditions
Hepatitis C
Interventions
DCV 3DAA FDC, BMS-791325
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2014 · Synced Jul 23, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Results available

Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer

NCT00459875
View directory record Official record
Conditions
Kidney Cancer
Interventions
sunitinib malate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Jul 23, 2026, 10:45 PM EDT
Active, not recruiting No phase listed Observational

Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)

NCT05520099
View directory record Official record
Conditions
Immunotherapy, Cancer, Bladder Cancer, Urothelial Carcinoma Bladder, Kidney Cancer, Clear Cell Renal Cell Cancer (ccRCC), Colorectal Cancer, MSI-H Colorectal Cancer, DMMR Colorectal Cancer, Head and Neck Cancer (H&N), Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), Liver Cancer, Hepatocellular Carcinoma (HCC), Lung Cancer (NSCLC), NSCLC (Non-small Cell Lung Cancer), Skin Cancer, Cutaneous Melanoma, Endometrial Cancer, Solid Tumor Cancer
Interventions
Core Needle Biopsy, Forceps Biopsy, Punch Biopsy
Procedure
Lead sponsor
Elephas
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
12
States / cities
Little Rock, Arkansas • Salinas, California • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 23, 2026, 10:45 PM EDT
Completed Phase 1 Interventional

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

NCT01183663
View directory record Official record
Conditions
Advanced Cancers
Interventions
Lenalidomide, Bevacizumab, Sorafenib, Temsirolimus, Oxaliplatin, Leucovorin, 5-fluorouracil
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Jul 23, 2026, 10:45 PM EDT
Completed Phase 3 Interventional

Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients

NCT00561093
View directory record Official record
Conditions
Hypoalbuminemia, Protein-energy Malnutrition, Inflammation, Oxidative Stress, Chronic Kidney Disease (CKD) Hemodialysis
Interventions
pentoxiphylline, Nepro, anti-inflammatory module (similar to Oxepa), Placebo pill imitating pentoxiphylline, Placebo to imitate Nepro, Placebo to imitate anti-inflammatory module (similar to Oxepa)
Drug · Dietary Supplement
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Irvine, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Jul 23, 2026, 10:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021)

NCT04994522
View directory record Official record
Conditions
End Stage Renal Disease, Renal Impairment
Interventions
Belzutifan
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Jul 23, 2026, 10:45 PM EDT
Completed Phase 1 Interventional

RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma

NCT00101972
View directory record Official record
Conditions
Cancer
Interventions
monoclonal antibody RAV12
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
5
States / cities
Santa Monica, California • Washington D.C., District of Columbia • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Jul 23, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Results available

LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)

NCT04402957
View directory record Official record
Conditions
COVID, Severe Acute Respiratory Syndrome, Sars-CoV2, Acute Kidney Injury, Acute Respiratory Distress Syndrome
Interventions
LSALT peptide, Placebo
Drug
Lead sponsor
Arch Biopartners Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
San Diego, California • Fort Lauderdale, Florida • Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Jul 23, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Results available

Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency

NCT01958281
View directory record Official record
Conditions
HCV Infection
Interventions
SOF, RBV, LDV/SOF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
7
States / cities
San Francisco, California • Miami, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Jul 23, 2026, 10:45 PM EDT
Completed Phase 1 Interventional Results available

HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis

NCT03934736
View directory record Official record
Conditions
End Stage Renal Disease on Hemodialysis (Diagnosis)
Interventions
HEPLISAV-B®
Drug
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
20
States / cities
Bloomfield, Connecticut • Middlebury, Connecticut • Hollywood, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Jul 23, 2026, 10:45 PM EDT
Completed Not applicable Interventional

"Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)"

NCT05410509
View directory record Official record
Conditions
Renal Cell Carcinoma (RCC)
Interventions
Trans-arterial embolization (TAE)
Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Birmingham, Alabama • Stanford, California • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 23, 2026, 10:45 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Kidney Cancer

NCT00096629
View directory record Official record
Conditions
Kidney Cancer
Interventions
human prostate-specific membrane antigen plasmid DNA vaccine, mouse prostate-specific membrane antigen plasmid DNA vaccine
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Jul 23, 2026, 10:45 PM EDT
Recruiting No phase listed Observational

RETRO Study (RETrograde Renal Access Outcomes)

NCT07071831
View directory record Official record
Conditions
Renal Stones
Interventions
RetroPerc®
Device
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Tampa, Florida • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jul 23, 2026, 10:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF

NCT00458536
View directory record Official record
Conditions
Renal Cancer
Interventions
Dendritic Cell Tumor Fusion Vaccine, Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
Biological · Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 23, 2026, 10:45 PM EDT
Enrolling by invitation Not applicable Interventional

Goals of Care Conversations Study

NCT05001009
View directory record Official record
Conditions
Seriously Ill Patients, Cancer, Heart Failure, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, End-stage Renal Disease, End-stage Liver Disease, Dementia
Interventions
Clinician Implementation Strategy Stage 1: low intensity clinician training, Clinician Implementation Strategy Stage 2: high intensity clinician training, Low patient engagement, High patient engagement
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Palo Alto, California • West Los Angeles, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Jul 23, 2026, 10:45 PM EDT
Recruiting Phase 2 Interventional

Islet Transplantation in Type 1 Diabetic Kidney Allograft

NCT01241864
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Allogenic islet cells (human, U. Chicago), Intraportal infusion of islet cells
Biological · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 68 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Jul 23, 2026, 10:45 PM EDT
Active, not recruiting Phase 2 Interventional

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

NCT04940299
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Bladder Carcinoma, Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Renal Pelvis Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Malignant Solid Neoplasm, Metastatic Bladder Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Carcinoma, Metastatic Urethral Urothelial Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Stage III Bladder Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Bladder Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Lung Cancer AJCC v6, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Melanoma
Interventions
Ipilimumab, Nivolumab, Tocilizumab
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jul 23, 2026, 10:45 PM EDT
Not listed Phase 2 Interventional

Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease

NCT04939116
View directory record Official record
Conditions
Glomerular Disease, Proteinuria
Interventions
ANG-3070, Placebo
Drug
Lead sponsor
Angion Biomedica Corp
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
18
States / cities
Birmingham, Alabama • Northridge, California • Vacaville, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Jul 23, 2026, 10:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Over-the-counter Dietary Supplements on Kidney Stone Risk

NCT02404701
View directory record Official record
Conditions
Hyperoxaluria
Interventions
Aloe vera with cactus, Cranberry, Green tea extract, Bilberry, Cinnamon, Milk thistle, Turmeric, Aloe vera
Dietary Supplement
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Jul 23, 2026, 10:45 PM EDT
Active, not recruiting No phase listed Observational

A Pilot Study of Blood-based Biomarkers for Response to Immune Checkpoint Inhibitors

NCT06630429
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Renal Cell Carcinoma (RCC)
Interventions
Biospecimen Collection
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Timeline
2020 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jul 23, 2026, 10:45 PM EDT